US4296130A - Methylsulfonylmethane and methods of use - Google Patents
Methylsulfonylmethane and methods of use Download PDFInfo
- Publication number
- US4296130A US4296130A US06/071,068 US7106879A US4296130A US 4296130 A US4296130 A US 4296130A US 7106879 A US7106879 A US 7106879A US 4296130 A US4296130 A US 4296130A
- Authority
- US
- United States
- Prior art keywords
- msm
- skin
- carbamide
- compositions
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940016409 methylsulfonylmethane Drugs 0.000 title claims abstract description 187
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 title claims abstract description 187
- 238000000034 method Methods 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 claims abstract description 118
- 241001465754 Metazoa Species 0.000 claims abstract description 31
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000008280 blood Substances 0.000 claims abstract description 20
- 239000003085 diluting agent Substances 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 8
- 230000036770 blood supply Effects 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 153
- 239000004202 carbamide Substances 0.000 abstract description 77
- 235000013877 carbamide Nutrition 0.000 abstract description 76
- 239000000243 solution Substances 0.000 abstract description 59
- 239000000126 substance Substances 0.000 abstract description 31
- 238000002360 preparation method Methods 0.000 abstract description 23
- 230000008901 benefit Effects 0.000 abstract description 19
- 239000000499 gel Substances 0.000 abstract description 16
- 210000001124 body fluid Anatomy 0.000 abstract description 12
- 239000010839 body fluid Substances 0.000 abstract description 12
- 239000006071 cream Substances 0.000 abstract description 6
- 239000006210 lotion Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 230000003750 conditioning effect Effects 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 230000007935 neutral effect Effects 0.000 abstract description 2
- 238000011200 topical administration Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 62
- 210000001519 tissue Anatomy 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 238000009472 formulation Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 210000000282 nail Anatomy 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- 229920001436 collagen Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000002537 cosmetic Substances 0.000 description 13
- 210000002808 connective tissue Anatomy 0.000 description 11
- 238000004132 cross linking Methods 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 230000002411 adverse Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000004166 Lanolin Substances 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 229940039717 lanolin Drugs 0.000 description 7
- 235000019388 lanolin Nutrition 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000004761 scalp Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 3
- 229940043234 carbomer-940 Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000008257 shaving cream Substances 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000004905 finger nail Anatomy 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000004906 toe nail Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940024548 aluminum oxide Drugs 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960004822 erythromycin phosphate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OPWQFMMWSDUTSI-UHFFFAOYSA-N ethyl 2-aminobenzoate propyl hexadecanoate Chemical compound CCOC(=O)C1=CC=CC=C1N.CCCCCCCCCCCCCCCC(=O)OCCC OPWQFMMWSDUTSI-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008633 juniper tar Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- AOJBACHWNDMRQP-UHFFFAOYSA-N n,n-diethyl-4-methylbenzenesulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(C)C=C1 AOJBACHWNDMRQP-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
Definitions
- the present invention relates to compositions for conditioning the skin, nails, other tissue and/or body fluids of a human or other animal subject. More specifically, it relates to compositions which can be used to soften, smooth, lubricate and preserve the pliancy of human tissue, for reducing the brittleness of finger and toe nails, and as diluents for blood.
- lanolin must be applied to the skin frequently and in large quantities. Even then, the softening effect on the skin is less than has been obtained using lesser amounts of other skin softening substances. Compositions containing lanolin in sufficient quantity can leave the skin with a greasy feeling and may stain clothing if not thoroughly absorbed by the skin.
- carbamide urea
- Urea has been used with reasonable success for softening the skin and for treating skin disease.
- the carbamide is applied in an aqueous solution or in the form of a cream.
- Such carbamide preparations have had only limited utility, however, because the carbamide tends to spontaneously decompose.
- preservatives for the carbamide must be added if such a skin treating composition is to have a reasonable shelf life.
- DMSO dimethyl sulfoxide
- U.S. Pat. No. 3,549,770 DMSO has utility in relieving signs and symptoms of pain and tissue inflammation and for promoting tissue repair of a subject having a skin graft or suffering from burns or tissue damage. But, DMSO frequently causes adverse skin reactions so that DMSO has previously been considered unsuitable for use in cosmetics and other non-prescription preparations.
- dextran has become a widely accepted extender for blood plasma and is commonly used as a blood diluent.
- this substance has a higher and more variable molecular weight than most normal blood constituents; and many subjects who receive the substance react allergically.
- Other blood diluents have even greater drawbacks; so there is no universally accepted blood diluent or plasma expander.
- compositions containing methylsulfonylmethane can be used effectively to soften skin, to dilute blood, and for a variety of other useful purposes.
- MSM compositions are stable and safe for administration to human or other animal subjects and therefore eliminate many problems of the prior art.
- topically applied MSM compositions benefit the skin to a far greater degree than lanolin or carbamide.
- MSM can be combined with lanolin and/or carbamide to form skin preparations which are exceptionally effective.
- Manicuring preparations can advantageously include MSM. Such preparations can increase nail toughness by reducing brittleness and can be used for softening cuticle for easy removal.
- a preparation can contain MSM in solution or in a dispersion. It may take the form of a cream, lotion, gel or paste for topical administration or a liquid, solid or vapor for administration by other routes such as injection, inhalation, oral injestion and the like.
- MSM tends to stabilize compositions containing carbamide by inhibiting spontaneous carbamide decomposition.
- carbamide stabilizes MSM in compositions so that MSM and carbamide are exceptionally well suited for use together.
- DMSO may be included with certain MSM compositions to enhance their effectiveness.
- An aqueous composition with the proper concentration of MSM, is an excellent diluent for blood.
- MSM is nonallergenic, nonpyretic and has no interfering or undesirable pharmacological effect, even when administered in relatively large amounts for a blood diluent.
- MSM has a far lower molecular weight yet remains in the body longer than dextran.
- MSM is a naturally occurring substance found in the tissues and body fluids of at least all higher animals. It can be isolated from mammalian milk, e.g. cow's milk. It is also a naturally occurring excretory product in higher animals, such as man, where it is found in the urine.
- MSM is of exceedingly low toxicity to all forms of life, plant as well as animal. Except for its beneficial effect on animal tissue, it appears to be totally inert to the diverse chemical reactions involved in the processes of life.
- MSM used in cosmetic preparations and other preparations administered to tissue and/or body fluids of a human subject should be substantially pure. Accordingly an improved process for purification of MSM has been developed.
- a further object is to provide MSM compositions in a variety of forms and to provide a variety of methods of treatment with MSM in accord with the conditions or body parts to be treated.
- a particular related object is to provide such compositions in a viscous liquid form so that they can be easily applied topically and in an injectable liquid form so that they can be administered to subcutaneous tissue or body fluids.
- Yet another object is to provide methods for treating connective tissue of a human or animal subject to resist cross-linking of collagen and other protein in the tissue and reduce dehydration or other alteration of cementing substrates such as hyaluronic acid.
- An object is to provide a stable, neutral vehicle for pharmaceuticals, which vehicle has no interfering or undersirable pharmacological activity.
- An additional object is to provide an effective composition and method for reducing the brittleness of finger and toe nails.
- an object is to provide a method and composition for the softening of cuticle tissue so that it can be removed be gentle rubbing.
- a specific object is to provide a safe and universally acceptable blood diluent.
- Another object is to provide a method for purification of MSM to a purity at which it can be included in cosmetics or other preparations for administration to the tissue or body fluids of animal subjects.
- Methylsylfonulmethane is an active agent which can be used safely and effectively for treating human or other animal subjects. It can be administered by numerous routes for a variety of purposes.
- MSM can be included in a cosmetic or other preparations applied to the skin.
- Such compositions when applied topically, can beautify the complexion, improve the condition of the scalp and hair and help to make the body of the user more flexible and comfortable.
- Liquid cosmetic preparations can include MSM in aqueous or nonaqueous solutions or emulsions.
- compositions containing MSM may be in the form of an injectable liquid for subcutaneous application.
- the composition will preferably be a solution or emulsion containing thickeners suitable to form a cream, lotion or gel.
- MSM can be administered in a mixture, e.g. a mixture of MSM crystals and peanut oil, which is surgically implanted or in a dry compound of body powders. It can be included in syrups, tablets or capsules which are ingested to preserve the pliancy of intestinal and other tissue.
- MSM can be vaporized or dispersed in an aerosol for inhalation.
- Certain aqueous MSM compositions can be administered intravenously as nontoxic, nonallergenic blood diluents and modifiers of internal tissues.
- MSM A substantial advantage of MSM, regardless of how or why it is administered, is the noninteraction of MSM with the diverse chemical reactions involved in the process of life. Except for its inhibiting effect on cross-linking, MSM appears to be inert in the tissue and body fluids of living subjects.
- MSM can be combined with non-irritating solvents and/or emulsifiers to provide excellent vehicles for pharmaceutical substances. Such vehicles deliver the pharmaceutical and simultaneously improve the condition of the subject's connective tissue. Inertness further makes MSM a superior substance for formulating aqueous blood diluent solutions as will be further described below.
- MSM odorless, white, crystalline substance with a melting point of 109° C. and a boiling point of 238° C. It tends to sublime with heating. MSM has a molecular weight of 94.13, specific gravity of about 1.45 and an index of a refraction of 1.42 at 20° C.
- Preparations containing MSM in aqueous solution should generally contain only about 20 weight percent MSM and preferably no more than about 15 weight percent. Solutions containing MSM in greater concentrations can be formulated by using other pharmaceutically acceptable solvents, e.g. glycerine and/or ethanol. High concentration aqueous MSM compositions, suitable for certain specific purposes, can also be made by dissolving crystalline MSM in heated water immediately prior to application.
- MSM also works well in emulsions such as those formed with a polymer of acrylic acid cross-linked with a polyfunctional agent.
- a polymer of acrylic acid cross-linked with a polyfunctional agent is Carbopol 934P manufactured by B. F. Goodrich Chemical Company, Cleveland, Ohio.
- Other suitable emulsions can be formulated using modified cellulose polymers such as hydroxyethylcellulose.
- MSM When MSM is to be administered to human or other animal subjects it should be present in a composition which is pharmaceutically acceptable for the intended route of administration.
- the composition should not contain MSM in so great a concentration that it would be injurious; and the composition should not include unnecessarily toxic substances or substances which react with MSM to produce undesired substances.
- MSM softens or otherwise benefits animal skin
- a normal part of the aging process is the progressive cross-linking or bonding of protein such as collagen in animal connective tissue, especially skin.
- Such cross-links possibly covalent, hydrophobic or hydrogen bonds and/or van der Waals associations
- stiffen and harden the tissue stiffen and harden the tissue.
- MSM acts to soften and preserve the pliancy of connective tissue by inhibiting bond structing of connective tissue, protein and other components in the tissue, and possibly by attacking existing cross-links.
- the benefits observed when MSM is used may result from reductions in dehydration of body substances such as hyaluronic acid and elastin, or from beneficial effects of MSM on fibrinogen.
- MSM The amount of MSM to be included in a particular composition may vary greatly depending upon the intended use of the composition. When treating the naturally soft and pliant skin of infants, a composition containing even minute quantities of MSM may be beneficial when applied to the skin. When treating the connective tissue of adult subjects, MSM should comprise at least about one weight percent of the composition administered. Disproportionately superior results are achieved using compositions containing at least about five weight percent MSM.
- the maximum concentration of MSM in compositions for topical application is about 15 weight percent, preferably only about 10 weight percent. Greater amounts of MSM could, however, be used if the composition is heated and mixed prior to topical application.
- the following examples are provided to illustrate the activity of MSM in softening, smoothing and otherwise inhibiting the aging of skin and other animal tissue and to show the noninteractivity which makes MSM suitable for use in vehicles for pharmaceutical substances and in blood diluents.
- the examples are not to be taken as an exhaustive list of the possible methods for using MSM and the benefits resulting from its use. The examples do, however, give some indication of the broad scope of this invention, specifically the suitability of MSM for a variety of purposes.
- aqueous solution of MSM Five aqueous solution of MSM were prepared, the solutions containing 2, 4, 6, 8 and 10 weight percent of MSM, respectively. Each of the solutions was heated and combined with a sample of modified collagen at a weight ratio of nine to one. Normally, collagen combined with heated water will swell and form physical and chemical bonds to form a gel. However, when the mixtures of this experiment cooled to room temperature, no gelation had occurred in the mixtures containing 8 to 10 weight percent MSM solutions.
- carbamide urea
- MSM composition enhances the effectiveness of the composition as a tissue treating agent, beyond expectations.
- carbamide is known to have some beneficial effects when applied to the skin, it is not believed that carbamide alone has any effect in inhibiting chemical bond linking of collagen.
- compositions containing both MSM and carbamide have a much greater activity in inhibiting bond structuring of substances in connective tissue than compositions containing either one of the substances along. It appears that the presence of carbamide accelerates tissue penetration of MSM. Furthermore, experimental results show increased benefits beyond those expected to result from accelerated MSM penetration alone.
- compositions for application to the tissue of an animal subject even small amounts of carbamide may be helpful in improving the overall softness of the skin.
- the composition becomes especially effective, however, when carbamide is present in an amount effective to multiply the activity of the MSM.
- Such a composition will contain at least about one weight percent carbamide and preferably at least about 5 weight percent.
- Example 2 The procedure of Example 2 was repeated twice. In the first repetition, 2, 4, 6, 8 and 10 weight percent aqueous carbamide solutions, instead of MSM solutions, were added to five collagen samples. When the collagen samples had cooled to room temperature, it was observed that carbamide had no effect in reducing collagen cross-linking in any of the mixtures.
- aqueous solutions containing equal weights of both MSM and carbamide were mixed with the collagen samples.
- a first solution contained 2 weight percent each MSM and carbamide, a second 4 weight percent each, a third 6 weight percent each, a fourth 8 weight percent each; and a fifth solution contained 10 weight percent of each.
- compositions can be administered to animal tissue to counter the cross-linking of collagen which is associated with aging and various disease processes. It specifically appears that the softness and pliancy associated with youthful, healthy skin thus can be maintained and that unhealthy, abused, old skin at least partially can be restored.
- Sections of human cadaver skin were brought to a constant weight in a 50% relative humidity oven. The sections were divided into four groups. Each group of sections was immersed in a different aqueous solution as set forth in the following table:
- the sections were immersed for two hours, blotter dried and then stabilized at 50% relative humidity.
- the cadaver skin which can be expected to behave similarly to the outer layers of the epidermis of a healthy human, was found to retain less than 5% moisture when treated with the isotonic saline (Group 4) solution and then stabilized.
- the skin treated with solution containing MSM along (Group 2) was substantially more flexible and retained 30-35% mositure.
- the highest moisture levels and greatest flexibility was observed in the sections which were treated with both MSM and carbamide (Group 3).
- the sections treated with the carbamide solution (Group 2) showed some improved moisture retention, but less than that of the Group 3 sections.
- MSM may serve as an additive for embalming fluid to maintain tissue pliancy.
- compositions containing MSM and carbamide were made to determine the effectiveness of compositions containing MSM and carbamide in treating human subjects having skin with a thickened stratum corneum.
- a first solution containing 10 grams MSM, 45 grams water and 45 grams ethanol was applied three times daily to a human subject having skin with a thickened stratum corneum. After applications three times daily for a period of one week, a substantial softening and smoothing of the skin was observed.
- a second solution containing 10 grams carbamide, 45 grams water and 45 grams ethanol was applied to a human subject having skin with a thickened stratum corneum. After one week, small improvements in skin pliancy were observed; but there was no increase in softness or smoothness of the skin.
- a third solution containing 5 grams MSM, 5 grams carbamide, 45 grams water and 45 grams ethanol was applied to several human subjects having skin with a thickened stratum corneum. After a one week period of applications three times a day, the skin of these subjects was exceptionally soft and smooth in the areas of application. Even though the composition contained only 5 weight percent MSM, the extent of the physiological effect resulting from the application of this combined solution was greater than the effect which resulted from application of the first two solutions containing 10 weight percent MSM and 10 weight percent carbamide, respectively.
- each composition included a liquid comprising equal amounts, by volume, of water and ethanol.
- compositions were applied daily to separate subjects. And, the date was recorded for each subject when an increase in skin softness and smothness was first detected. The results of this testing were compiled and appear in the following table:
- compositions containing MSM and carbamide improve the softness and pliability of skin even of persons suffering from adverse skin conditions.
- two human subjects suffering from "hide bound disease” or progressive systemic sclerosis were poorly responsive to standard treatments for softening the skin and making hands and feet more comfortable.
- a preparation containing 20 weight percent MSM, 20 weight percent carbamide, 30 weight percent dimethyl sulfoxide and 30 weight percent water was prepared.
- a solution was formed by heating to about 40° C.
- the subjects were treated by placing 15 milliliters of the solution in a plastic bag, placing a hand or foot to be treated in the bag.
- the hand or foot with plastic bag overwrap was then immersed in a heated water bath maintained at a temperature as warm as the subject would tolerate, taking care not to dilute the solution.
- the hands and feet were thus immersed for 30 minutes, 3 times daily, for a period of 2 weeks.
- the result was a reduction in discomfort and an increased skin softness and pliancy.
- Dimethyl sulfoxide was used in the solution to enhance penetration of MSM and carbamide into the effected tissue. No adverse side-effects resulted from administration of the DMSO.
- compositions containing MSM and carbamide can be applied to skin which is injured or inflammed without causing adverse reactions.
- a gel containing MSM and carbamide was made according to the following formulation:
- This formulation was applied to the skin of subjects having a variety of adverse skin conditions including diaper rash, abrasions, wind burns, thermal burn and skin tears from berry bushes. In none of these applications did the subjects experience instantaneous discomfort of the type frequently encountered when medical preparations were applied. In a number of instances the preparation was soothing to the effected skin and provided a protective coating for the affected area.
- MSM and carbamide can be used effectively in more complex compositions, such as the creams, lotions and gels which are most preferred for cosmetics preparations.
- One such formulation a gel containing Carbopol 940 as a thickening agent, was made by combining the following ingredients:
- MSM can also be added to a variety of cosmetic preparations other than skin lotions, creams and gels.
- a shampoo was formulated with the following ingredients:
- This shampoo formulation was tested both by subjects with healthy hair scalp and by others with problem seborrheic dermatitis. Both groups found the shampoo to be effective, to leave the hair easily manageable and to soften the scalp. Those subjects having a dandruff problem found there was a reduction in itching, scaling and scalp inflammation after only four to five washings.
- a hair styling gel including MSM and carbamide was prepared according to the following formulation:
- this composition When applied to the hair of human subjects, this composition proved to be more effective in hair management than a comparable commercial product.
- leg hair was easily shaved without a commercial shaving cream overcoat. In all instances, use of the formulation left the skin feeling softer and smoother.
- a nail conditioner was formulated from the following ingredients:
- the formulation was applied with cotton pads to the nails of human subjects and allowed to remain for at least 15 minutes. At the end of that time, the nails were toughened, i.e. less brittle, and the cuticle was softened such that it could be removed by gentle rubbing.
- DMSO dimethylsulfoxide
- Nail polishes containing MSM were formulated by preparing 25 weight percent MSM solutions in ethyl or amyl acetate. Such solutions were mixed with the commercial nail polishes of several well-known U.S. manufacturers in such a ratio that the resulting mixtures contained about 5 weight percent MSM.
- a 40 weight percent solution of MSM in distilled water was prepared. This solution was administered orally to laboratory rats at such a rate that each rat received 20 grams of MSM per kilogram of body weight per day.
- MSM is substantially inert to the chemistry of the body, compositions containing this substance are excellent vehicles for pharmaceuticals. When applied, the MSM will produce the desirable results mentioned above. MSM does not react with common pharmaceutical substances. And, as discussed below, MSM can actually stabilize certain substances such as carbamide so that the shelf life of certain pharmaceutical preparations can be extended by the inclusion of MSM
- Example 9 The formulation of Example 9 was evaluated as a potential vehicle for agents known to have beneficial cosmetic, skin treating and/or insect repelling activities. A variety of compositions were made using the formulation of Example 9 as a vehicle.
- Example 9 a 150 gram sample of the formulation described in Example 9 was combined, in a household, high sheer mixer, with 10 grams of an active agent and the resulting combination thoroughly mixed. Combined formulations were made in this manner with each of the following agents:
- Example 9 All of the compositions formed were stable. When applied to the skin, each composition produced the desirable tissue softening effects described in Example 9 without reducing the effectiveness of the agent. From this sampling it is logical to conclude that formulation of Example 9 could be very beneficial as a vehicle for a wide variety of pharmaceutical and cosmetic substances
- compositions containing both MSM and carbamide are more stable than similar compositions containing MSM or carbamide alone, apparently because MSM and carbamide stabilize one another.
- MSM is thus useful as a stabilizer in almost any composition which contains the carbamide subject to spontaneous decomposition and vice versa.
- Example 8 To demonstrate the ability of MSM to inhibit the spontaneous decomposition of carbamide, laboratory tests were conducted. In these tests, the gel described in Example 8 was compared with a control formula that was an identical gel except that it contained no MSM. Multiple samples of each formula were placed in plastic coated metal tubes that were sealed and capped
- Tubes containing each formulation were subjected to successive freeze-thaw cycles.
- the formulation without MSM began to break down to a liquid after two to three such cycles; while no break down of the composition including MSM was observed after ten freeze-thaw cycles.
- MSM monostyrene-maleic anhydride
- An MSM composition for use as blood diluent should be formulated as a solution which will create substantially the same oncotic pressure as normal plasma of the blood to be diluted.
- the MSM should comprise between 0.1 and 50 weight percent of the composition. Use of the MSM amounts at the low end of this range presumes the presence of other dissolved substances which, together with the MSM, cause the solution to have substantially the same oncotic pressure as the body fluid to be diluted.
- MSM was dissolved in a standard 5 percent dextrose solution so that the resulting liquid composition contained 20 weight pe-cent MSM.
- the composition was delivered intravenously to a dog weighing 9.5 kilograms at such a rate that the subject received 2 grams of MSM per kilogram of body weight per day.
- the subject did not react adversely to the intravenous administrations and did not require physical restraint. After several weeks of this treatment there was no evidence of physical discomfort or injury to the subject.
- MSM is combined with heated water to form a solution, the temperature of the water determining the amount of MSM which can be dissolved for purification.
- Activated charcoal is then added to the solution along with a substantially water insoluble base, such as aluminum or magnesium hydroxide, in an amount effective to neutralize the solution.
- the charcoal and base are then mechanically separated from the solution and the solution cooled to a temperature where purified MSM crystalizes. In most instances, crystals form when a solution is cooled to 10° C.; but enhanced crystallization occurs when the solution is cooled to below 5° C.
- the purified MSM are then mechanically separated form the water. The remaining water still contains some dissolved MSM. Losses of MSM can thus be minimized by recycling the water for use as a solvent to purify additional MSM crystals according to this process.
- MSM produced by this process was extremely pure and thus suitable for use in any appropriate composition to be applied to human tissue or body fluids.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/071,068 US4296130A (en) | 1979-08-30 | 1979-08-30 | Methylsulfonylmethane and methods of use |
CA000357803A CA1157380A (fr) | 1979-08-30 | 1980-08-07 | Preparations renferment du methylsulfonylmethane, et methodes d'utilisation et de purification |
GB8026293A GB2057263B (en) | 1979-08-30 | 1980-08-12 | Compositions containing methylsulphonylmethane |
AU61833/80A AU544254B2 (en) | 1979-08-30 | 1980-08-28 | Methods |
FR8018677A FR2464069A1 (fr) | 1979-08-30 | 1980-08-28 | Compositions a base de methylsulfonylmethane, procede pour leur purification et leurs utilisations notamment en therapeutique |
DE19803032462 DE3032462A1 (de) | 1979-08-30 | 1980-08-28 | Praeparate zur anwendung an oder in geweben und/oder fluessigkeiten des menschlichen oder tierischen koerpers |
IT24369/80A IT1193965B (it) | 1979-08-30 | 1980-08-29 | Preparazione contenente metilsolfonilmetano e procedimenti per l'impiego e la purificazione di essa |
JP11903980A JPS5636412A (en) | 1979-08-30 | 1980-08-30 | Methylsulfonylmethaneecontaining composition* its use and purification |
US06/277,592 US4477469A (en) | 1979-08-30 | 1981-06-26 | Preparations containing methylsulfonylmethane and methods of use and purification |
US06/418,110 US4514421A (en) | 1979-08-30 | 1982-09-14 | Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it |
US06/584,354 US4568547A (en) | 1979-08-30 | 1984-02-28 | Solid pharmaceutical compositions comprising MSM and their production |
US06/727,989 US4616039A (en) | 1979-08-30 | 1985-04-29 | Methylsulfonylmethane in dietary products |
SG413/85A SG41385G (en) | 1979-08-30 | 1985-05-30 | Preparations containing methylsulfonylmethane and method of purification |
HK680/85A HK68085A (en) | 1979-08-30 | 1985-09-05 | Preparations containing methylsulfonylmethane and method of purification |
US06/878,948 US4863748A (en) | 1979-08-30 | 1986-06-26 | Dietary products and uses comprising methylsulfonylmethane |
US07/385,117 US4973605A (en) | 1979-08-30 | 1989-07-26 | Use of methylsulfonylmethane to relieve pain and relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals |
US07/385,116 US4914135A (en) | 1979-08-30 | 1989-07-26 | Use of Methylsulfonylmethane to treat parasitic infections |
US07/654,856 US5071878A (en) | 1979-08-30 | 1991-02-06 | Use of methylsulfonylmethane to enhance diet of an animal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/071,068 US4296130A (en) | 1979-08-30 | 1979-08-30 | Methylsulfonylmethane and methods of use |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/277,592 Division US4477469A (en) | 1979-08-30 | 1981-06-26 | Preparations containing methylsulfonylmethane and methods of use and purification |
US07/385,117 Division US4973605A (en) | 1979-08-30 | 1989-07-26 | Use of methylsulfonylmethane to relieve pain and relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals |
Publications (1)
Publication Number | Publication Date |
---|---|
US4296130A true US4296130A (en) | 1981-10-20 |
Family
ID=22099046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/071,068 Expired - Lifetime US4296130A (en) | 1979-08-30 | 1979-08-30 | Methylsulfonylmethane and methods of use |
Country Status (10)
Country | Link |
---|---|
US (1) | US4296130A (fr) |
JP (1) | JPS5636412A (fr) |
AU (1) | AU544254B2 (fr) |
CA (1) | CA1157380A (fr) |
DE (1) | DE3032462A1 (fr) |
FR (1) | FR2464069A1 (fr) |
GB (1) | GB2057263B (fr) |
HK (1) | HK68085A (fr) |
IT (1) | IT1193965B (fr) |
SG (1) | SG41385G (fr) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0103836A2 (fr) * | 1982-09-14 | 1984-03-28 | Robert J. Herschler | Compositions diététiques et pharmaceutiques à base de méthylsulfonylméthane |
US4568547A (en) * | 1979-08-30 | 1986-02-04 | Herschler R J | Solid pharmaceutical compositions comprising MSM and their production |
EP0200526A2 (fr) | 1985-04-29 | 1986-11-05 | Robert J. Herschler | Produits diététiques contenant du méthylsulfonylméthane et utilisations de ce produit |
US4663233A (en) * | 1985-10-24 | 1987-05-05 | Universal High Technologies | Lens with hydrophilic coating |
US4801475A (en) * | 1984-08-23 | 1989-01-31 | Gregory Halpern | Method of hydrophilic coating of plastics |
US4863748A (en) * | 1979-08-30 | 1989-09-05 | Herschler R J | Dietary products and uses comprising methylsulfonylmethane |
US4914135A (en) * | 1979-08-30 | 1990-04-03 | Herschler R J | Use of Methylsulfonylmethane to treat parasitic infections |
US6399093B1 (en) | 1999-05-19 | 2002-06-04 | Advanced Medical Instruments | Method and composition to treat musculoskeletal disorders |
US6403116B1 (en) | 2000-11-03 | 2002-06-11 | Triarco Inductries, Inc. | Coenzyme Q10 formulation |
US20020182260A1 (en) * | 1998-05-29 | 2002-12-05 | Cellegy Pharmaceuticals, Inc. | Anti-inflammatory agents and methods for their preparation and use |
US6517822B1 (en) * | 1998-02-13 | 2003-02-11 | Carol J. Buck | Formulations and methods for straightening hair |
US6573299B1 (en) | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
US20030206884A1 (en) * | 2000-12-01 | 2003-11-06 | Aard-Balm Limited | Embalming fluid |
US6663874B2 (en) | 1998-11-02 | 2003-12-16 | Victor Stevens | Composition to alleviate pain and topical method of applying same |
US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
US20040038864A1 (en) * | 2002-06-27 | 2004-02-26 | Per Balschmidt | Use of dimethyl sulfone as isotonicity agent |
FR2848827A1 (fr) * | 2002-12-24 | 2004-06-25 | Oreal | Utilisation de dialkylsulfones dans des compositions cosmetiques de soin des ongles pour favoriser la pousse de l'ongle |
US20040180016A1 (en) * | 1998-02-13 | 2004-09-16 | Buck Carol J. | Formulations and methods for straightening hair |
US20040247544A1 (en) * | 2002-12-24 | 2004-12-09 | L'oreal | Use of dialkyl sulphones in cosmetic nailcare compositions for promoting growth of the nails |
US20050053635A1 (en) * | 2003-07-18 | 2005-03-10 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
US20050226827A1 (en) * | 2004-04-09 | 2005-10-13 | Thienna Ho | Skin lightening composition |
WO2005117913A3 (fr) * | 2004-04-20 | 2006-03-16 | De Pirillo Haydee Alba Stenti | Composition pharmaceutique ozonisee et procede associe |
US20060147423A1 (en) * | 2004-12-07 | 2006-07-06 | Jean-Yves Legendre | Transungual device |
US20060166879A1 (en) * | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
US20060177398A1 (en) * | 2003-03-05 | 2006-08-10 | Concept Laboratories | Sunless tanning products and processes |
US20070140999A1 (en) * | 2003-07-18 | 2007-06-21 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
US7282225B1 (en) | 2006-09-27 | 2007-10-16 | Occular Technologies, Inc. | Composition and methods for improving retinal health |
WO2010141098A1 (fr) * | 2009-06-03 | 2010-12-09 | Zerran International Corporation | Composition et procédé de défrisage et frisage capillaire |
US20110105623A1 (en) * | 2009-10-30 | 2011-05-05 | Biogenic Innovations, Llc | Use of methylsulfonylmethane (msm) to modulate microbial activity |
US7955418B2 (en) | 2005-09-12 | 2011-06-07 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated with same |
US8435224B2 (en) | 2005-09-12 | 2013-05-07 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds |
US8480797B2 (en) | 2005-09-12 | 2013-07-09 | Abela Pharmaceuticals, Inc. | Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
US8546373B2 (en) | 2009-10-30 | 2013-10-01 | Biogenic Innovations, Llc | Methods of sensitizing drug resistant microorganisms using methylsulfonylmethane (MSM) |
US8673061B2 (en) | 2005-09-12 | 2014-03-18 | Abela Pharmaceuticals, Inc. | Methods for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
WO2015033316A1 (fr) * | 2013-09-09 | 2015-03-12 | Iros R.C. S.R.L. | Compositions cosmétiques contenant une combinaison d'ingrédients actifs naturels |
US9427419B2 (en) | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
US9782372B2 (en) | 2013-03-15 | 2017-10-10 | Moberg Pharma Ab | Pharmaceutical composition for the treatment of fungal infections |
WO2018127702A1 (fr) | 2017-01-06 | 2018-07-12 | Stabilitech Biopharma Ltd | Virus |
US10980791B1 (en) | 2018-01-26 | 2021-04-20 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
US11369558B1 (en) * | 2018-01-26 | 2022-06-28 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5922980A (ja) * | 1982-07-29 | 1984-02-06 | Nitto Electric Ind Co Ltd | テ−プ製剤 |
JPH0725650B2 (ja) * | 1984-11-13 | 1995-03-22 | 株式会社粘土科学研究所 | ソジウム・モンモリロナイト、尿素複合体を主成分とする化粧料 |
JPS627A (ja) * | 1985-03-04 | 1987-01-06 | Shiseido Co Ltd | 尿素配合皮膚外用剤 |
GB8617482D0 (en) * | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
GB9218711D0 (en) * | 1992-09-04 | 1992-10-21 | Salim Aws S M | Skin cancer treatment |
AU4974893A (en) * | 1992-09-04 | 1994-03-29 | Aws Shakir Mustafa Salim | Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol |
GB9218714D0 (en) * | 1992-09-04 | 1992-10-21 | Salim Aws S M | Synergistic compositions for hair restoration |
GB9218715D0 (en) * | 1992-09-04 | 1992-10-21 | Salim Aws S M | Synergistic biologically skin moisturizer |
GB9218701D0 (en) * | 1992-09-04 | 1992-10-21 | Salim Aws S M | Housewife dermatitis treatment |
AU4974693A (en) * | 1992-09-04 | 1994-03-29 | Aws Shakir Mustafa Salim | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid |
JP2006008516A (ja) * | 2004-06-21 | 2006-01-12 | Nippon Kenko Kagaku Kenkyu Center:Kk | 鼻孔花粉症予防用軟膏、及び、鼻孔花粉症予防用ステック状軟膏 |
FR2878745B1 (fr) * | 2004-12-07 | 2007-03-09 | Oreal | Dispositif transungeal |
EP1886676A1 (fr) * | 2006-08-09 | 2008-02-13 | Polichem S.A. | Compositions avec une activité élastique améliorée |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3666863A (en) * | 1968-03-06 | 1972-05-30 | Medisan Ab | Skin-treating composition and vehicle for skin-treating agents |
DE2300594A1 (de) | 1972-01-10 | 1973-07-19 | Medisan Ab | Hautbehandlungsmittel und traegerstoffe fuer hautbehandlungsmittel |
US4122946A (en) * | 1977-05-18 | 1978-10-31 | Lane Container Company | Interfitting shipping pad |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1135784A (en) * | 1965-05-20 | 1968-12-04 | Canada Packers Ltd | Improved heparin and heparinoid compositions |
IL26209A (en) * | 1965-08-02 | 1970-10-30 | Merck & Co Inc | Pharmaceutical compositions containing substituted sulphones |
-
1979
- 1979-08-30 US US06/071,068 patent/US4296130A/en not_active Expired - Lifetime
-
1980
- 1980-08-07 CA CA000357803A patent/CA1157380A/fr not_active Expired
- 1980-08-12 GB GB8026293A patent/GB2057263B/en not_active Expired
- 1980-08-28 FR FR8018677A patent/FR2464069A1/fr active Granted
- 1980-08-28 AU AU61833/80A patent/AU544254B2/en not_active Expired
- 1980-08-28 DE DE19803032462 patent/DE3032462A1/de active Granted
- 1980-08-29 IT IT24369/80A patent/IT1193965B/it active
- 1980-08-30 JP JP11903980A patent/JPS5636412A/ja active Granted
-
1985
- 1985-05-30 SG SG413/85A patent/SG41385G/en unknown
- 1985-09-05 HK HK680/85A patent/HK68085A/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3666863A (en) * | 1968-03-06 | 1972-05-30 | Medisan Ab | Skin-treating composition and vehicle for skin-treating agents |
DE2300594A1 (de) | 1972-01-10 | 1973-07-19 | Medisan Ab | Hautbehandlungsmittel und traegerstoffe fuer hautbehandlungsmittel |
US4122946A (en) * | 1977-05-18 | 1978-10-31 | Lane Container Company | Interfitting shipping pad |
Non-Patent Citations (1)
Title |
---|
Chem. Abst., vol. 82; 11215t (1975). * |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4568547A (en) * | 1979-08-30 | 1986-02-04 | Herschler R J | Solid pharmaceutical compositions comprising MSM and their production |
US4863748A (en) * | 1979-08-30 | 1989-09-05 | Herschler R J | Dietary products and uses comprising methylsulfonylmethane |
US4914135A (en) * | 1979-08-30 | 1990-04-03 | Herschler R J | Use of Methylsulfonylmethane to treat parasitic infections |
US4514421A (en) * | 1979-08-30 | 1985-04-30 | Herschler R J | Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it |
EP0103836B1 (fr) * | 1982-09-14 | 1991-01-23 | Robert J. Herschler | Compositions diététiques et pharmaceutiques à base de méthylsulfonylméthane |
EP0103836A2 (fr) * | 1982-09-14 | 1984-03-28 | Robert J. Herschler | Compositions diététiques et pharmaceutiques à base de méthylsulfonylméthane |
WO1984001105A1 (fr) * | 1982-09-14 | 1984-03-29 | Herschler R J | Utilisations dietetiques et pharmaceutiques du methylsulfonylmethane et compositions le comprenant |
AU599670B2 (en) * | 1982-09-14 | 1990-07-26 | Robert J. Herschler | Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it |
US4801475A (en) * | 1984-08-23 | 1989-01-31 | Gregory Halpern | Method of hydrophilic coating of plastics |
EP0200526A2 (fr) | 1985-04-29 | 1986-11-05 | Robert J. Herschler | Produits diététiques contenant du méthylsulfonylméthane et utilisations de ce produit |
EP0200526A3 (en) * | 1985-04-29 | 1989-02-15 | Robert J. Herschler | Dietary products comprising, and uses of methylsulfonylmethane |
US4663233A (en) * | 1985-10-24 | 1987-05-05 | Universal High Technologies | Lens with hydrophilic coating |
US6517822B1 (en) * | 1998-02-13 | 2003-02-11 | Carol J. Buck | Formulations and methods for straightening hair |
US20040180016A1 (en) * | 1998-02-13 | 2004-09-16 | Buck Carol J. | Formulations and methods for straightening hair |
US20020182260A1 (en) * | 1998-05-29 | 2002-12-05 | Cellegy Pharmaceuticals, Inc. | Anti-inflammatory agents and methods for their preparation and use |
US6663874B2 (en) | 1998-11-02 | 2003-12-16 | Victor Stevens | Composition to alleviate pain and topical method of applying same |
US6399093B1 (en) | 1999-05-19 | 2002-06-04 | Advanced Medical Instruments | Method and composition to treat musculoskeletal disorders |
US6573299B1 (en) | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
US6403116B1 (en) | 2000-11-03 | 2002-06-11 | Triarco Inductries, Inc. | Coenzyme Q10 formulation |
US8015677B2 (en) * | 2000-12-01 | 2011-09-13 | Aard-Balm Limited | Embalming fluid |
US20030206884A1 (en) * | 2000-12-01 | 2003-11-06 | Aard-Balm Limited | Embalming fluid |
US20040038864A1 (en) * | 2002-06-27 | 2004-02-26 | Per Balschmidt | Use of dimethyl sulfone as isotonicity agent |
US20040029774A1 (en) * | 2002-08-06 | 2004-02-12 | Aly Gamay | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies |
US20060166879A1 (en) * | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
FR2848827A1 (fr) * | 2002-12-24 | 2004-06-25 | Oreal | Utilisation de dialkylsulfones dans des compositions cosmetiques de soin des ongles pour favoriser la pousse de l'ongle |
US20040247544A1 (en) * | 2002-12-24 | 2004-12-09 | L'oreal | Use of dialkyl sulphones in cosmetic nailcare compositions for promoting growth of the nails |
EP1475072A1 (fr) * | 2002-12-24 | 2004-11-10 | L'oreal | Utilisation de dialdylsulfones dans des compositions cosmetiques de soin des ongles pour favoriser la pousse de l'ongle |
US8182794B2 (en) * | 2003-03-05 | 2012-05-22 | Concept Laboratories | Sunless tanning products and processes |
US20060177398A1 (en) * | 2003-03-05 | 2006-08-10 | Concept Laboratories | Sunless tanning products and processes |
US7169401B2 (en) * | 2003-07-18 | 2007-01-30 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
US20070140999A1 (en) * | 2003-07-18 | 2007-06-21 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
US20050053635A1 (en) * | 2003-07-18 | 2005-03-10 | Hill Dermaceuticals, Inc. | Topical skin care composition containing refined peanut oil |
US20050226827A1 (en) * | 2004-04-09 | 2005-10-13 | Thienna Ho | Skin lightening composition |
WO2005099657A1 (fr) * | 2004-04-09 | 2005-10-27 | Thienna, Inc. | Methode d'eclaircissement de la peau |
US20070264212A1 (en) * | 2004-04-09 | 2007-11-15 | Thienna Ho | Skin Lightening Method |
US8293801B2 (en) * | 2004-04-09 | 2012-10-23 | Thienna Ho | Skin lightening method |
WO2005117913A3 (fr) * | 2004-04-20 | 2006-03-16 | De Pirillo Haydee Alba Stenti | Composition pharmaceutique ozonisee et procede associe |
US20070254963A1 (en) * | 2004-04-20 | 2007-11-01 | Haydee Stenti De Pirillo | Ozonidzed Pharmaceutical Composition and Method |
AU2005249370B2 (en) * | 2004-04-20 | 2010-10-28 | Carlos Alberto Pastoriza | Ozonized pharmaceutical composition and method |
US20060147423A1 (en) * | 2004-12-07 | 2006-07-06 | Jean-Yves Legendre | Transungual device |
US9427419B2 (en) | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
US8673061B2 (en) | 2005-09-12 | 2014-03-18 | Abela Pharmaceuticals, Inc. | Methods for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
US7955418B2 (en) | 2005-09-12 | 2011-06-07 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated with same |
US9186472B2 (en) | 2005-09-12 | 2015-11-17 | Abela Pharmaceuticals, Inc. | Devices for removal of dimethyl sulfoxide (DMSO) or related compounds or associated odors and methods of using same |
US9186297B2 (en) | 2005-09-12 | 2015-11-17 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds |
US8298320B2 (en) | 2005-09-12 | 2012-10-30 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same |
US8435224B2 (en) | 2005-09-12 | 2013-05-07 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds |
US8440001B2 (en) | 2005-09-12 | 2013-05-14 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same |
US8480797B2 (en) | 2005-09-12 | 2013-07-09 | Abela Pharmaceuticals, Inc. | Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
US7282225B1 (en) | 2006-09-27 | 2007-10-16 | Occular Technologies, Inc. | Composition and methods for improving retinal health |
WO2010141098A1 (fr) * | 2009-06-03 | 2010-12-09 | Zerran International Corporation | Composition et procédé de défrisage et frisage capillaire |
US8841100B2 (en) | 2009-10-30 | 2014-09-23 | Biogenic Innovations, Llc | Use of methylsulfonylmethane (MSM) to modulate microbial activity |
US9487749B2 (en) | 2009-10-30 | 2016-11-08 | Biogenic Innovations, Llc | Use of methylsulfonylmethane (MSM) to modulate microbial activity |
US20110136210A1 (en) * | 2009-10-30 | 2011-06-09 | Biogenic Innovations, Llc | Use of methylsulfonylmethane (msm) to modulate microbial activity |
US10596109B2 (en) | 2009-10-30 | 2020-03-24 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases |
US8217085B2 (en) | 2009-10-30 | 2012-07-10 | Biogenic Innovations, Llc | Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms |
US20110105623A1 (en) * | 2009-10-30 | 2011-05-05 | Biogenic Innovations, Llc | Use of methylsulfonylmethane (msm) to modulate microbial activity |
US20110152231A1 (en) * | 2009-10-30 | 2011-06-23 | Rodney Benjamin | Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms |
US8546373B2 (en) | 2009-10-30 | 2013-10-01 | Biogenic Innovations, Llc | Methods of sensitizing drug resistant microorganisms using methylsulfonylmethane (MSM) |
US9855212B2 (en) | 2009-10-30 | 2018-01-02 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases |
US9839609B2 (en) | 2009-10-30 | 2017-12-12 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis |
US9782372B2 (en) | 2013-03-15 | 2017-10-10 | Moberg Pharma Ab | Pharmaceutical composition for the treatment of fungal infections |
WO2015033316A1 (fr) * | 2013-09-09 | 2015-03-12 | Iros R.C. S.R.L. | Compositions cosmétiques contenant une combinaison d'ingrédients actifs naturels |
WO2018127702A1 (fr) | 2017-01-06 | 2018-07-12 | Stabilitech Biopharma Ltd | Virus |
US12016949B2 (en) | 2017-01-06 | 2024-06-25 | Iosbio Ltd | Virus |
US10980791B1 (en) | 2018-01-26 | 2021-04-20 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
US11369558B1 (en) * | 2018-01-26 | 2022-06-28 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
Also Published As
Publication number | Publication date |
---|---|
HK68085A (en) | 1985-09-13 |
JPH0227321B2 (fr) | 1990-06-15 |
AU544254B2 (en) | 1985-05-23 |
CA1157380A (fr) | 1983-11-22 |
DE3032462A1 (de) | 1981-03-19 |
GB2057263B (en) | 1984-05-31 |
SG41385G (en) | 1985-12-13 |
GB2057263A (en) | 1981-04-01 |
AU6183380A (en) | 1981-03-05 |
IT8024369A0 (it) | 1980-08-29 |
IT1193965B (it) | 1988-08-31 |
FR2464069B1 (fr) | 1983-11-18 |
DE3032462C2 (fr) | 1989-07-06 |
FR2464069A1 (fr) | 1981-03-06 |
JPS5636412A (en) | 1981-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4296130A (en) | Methylsulfonylmethane and methods of use | |
US4477469A (en) | Preparations containing methylsulfonylmethane and methods of use and purification | |
US4296104A (en) | Therapeutic dimethyl sulfoxide composition and methods of use | |
US5728391A (en) | Hyaluronic acid and its salt for treating skin diseases | |
US5234914A (en) | Methods of treating hemorrhoids and anorecial disease | |
CA1334280C (fr) | Gels aqueux contenant des medicaments topiques | |
US4387107A (en) | Stable benzoyl peroxide composition | |
US5624915A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
US5425954A (en) | Topical amino acid - vitamin complex compositions for pharmaceutical and cosmetic use | |
EP0954278B1 (fr) | Compositions pharmaceutiques contenant de l'huile de noix de kukui | |
JPH10226637A (ja) | 皮膚製剤 | |
US5137718A (en) | Infection fighting composition for topical application | |
JPH02501739A (ja) | ステロイドローション剤 | |
US5098717A (en) | Method of treatment for pruritus | |
US5258391A (en) | Phenyl alpha acyloxyalkanoic acids, derivatives and their therapeutic use | |
CA2152398A1 (fr) | Compositions pharmaceutiques a base d'acide hyaluronique et d'uree; applications | |
US6465514B1 (en) | Methods and compositions for the promotion of hair growth | |
US5176918A (en) | Topical medicament | |
US5435997A (en) | Topical agent and method for the treatment of pseudofolliculitis barbae | |
Ricciatti-Sibbald et al. | Dermatologic vehicles | |
JPH10510851A (ja) | 神経線維の反応性を変える化合物に基づく組成物 | |
JPH11500730A (ja) | 傷跡組織の局所的治療方法及び外傷に対し関連する組織反応 | |
WO2001007035A1 (fr) | Utilisation de tosylchloramide(s) pour le traitement de maladies de la peau, de la muqueuse, d'organes et de tissus | |
US4272516A (en) | Process for improving transcutaneous and transfollicular absorption of cosmetic compositions | |
RU2190388C1 (ru) | Средство на основе масла чайного дерева (варианты) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: CARDINAL ASSOCIATES, INC. DBA BERGSTROM NUTRITION, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HERSCHLER, ROBERT JOHN;REEL/FRAME:019280/0200 Effective date: 20070420 |